Table 1 General information of patients with IAD.

Gender (male/female)

8/5

7/6

1/1

16/12

Age, years, mean ± SD

63.0 ± 9.5

58.8 ± 11.5

65

61.2 ± 10.9

Occurrence time, weeks, median (IQR)

IAD

27 (18–40)

24 (21–33)

18.5

24 (18–39)

PHT

-

24 (21–42)

-

FT1DM

-

-

18.5

Type of tumor, n/ total n

Cervical cancer

1/13

1/13

-

2/28

Nasopharyngeal carcinoma

1/13

-

-

1/28

Lung cancer

2/13

2/13

1/2

5/28

Esophageal cancer

1/13

2/13

-

3/28

Gastric carcinoma

-

1/13

-

1/28

Hepatocellular carcinoma

2/13

3/13

-

5/28

Intrahepatic cholangiocarcinoma

3/13

1/13

-

4/28

Renal cell carcinoma

2/13

2/13

-

4/28

Melanoma

1/13

1/13

-

2/28

Breast cancer

-

-

1/2

1/28

ICIs (dosage, weeks), n/ total n

sintilimab (200 mg, q3w)

3/13

6/13

1/2

10/28

pembrolizumab (200 mg, q3w)

6/13

1/13

-

7/28

toripalimab (240 mg, q3w)

2/13

-

-

2/28

camrelizumab (200 mg, q2w)

2/13

2/13

-

4/28

tislelizumab (240 mg, q2w)

-

1/13

-

1/28

nivolumab (unknown, q2w)

-

1/13

-

1/28

atezolizumab (1200 mg, q3w)

-

-

1/2

1/28

Drug A in clinical trial (unknown, q3w)

-

1/13

-

1/28

Drug B in clinical trial (unknown, q2w)

-

1/13

-

1/28

Other combination therapy, n/ total n

chemotherapy

2/13

1/13

1/2

4/28

anlotinib

1/13

2/13

-

3/28

lenvatinib

2/13

1/13

-

3/28

apatinib

1/13

-

-

1/28